Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis

Table 7

Univariate and multivariate logistic regression risk models of the risk of relapse of MG (membrane-bound molecules).

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
CD4^+OX40 (%)	1.289 (1.132-1.469)	≤0.001	1.224 (1.048-1.429)	0.011
CD19^+OX40L (%)	0.985 (0.942-1.030)	0.518
CD14^+OX40L (%)	1.017 (0.963-1.075)	0.540
Sex, (%)
Male	Ref
Female	0.972 (0.332-2.845)	0.959
Age (years)	1.011 (0.980-1.044)	0.479
Follow-up (months)	0.994 (0.982-1.006)	0.302
MGFA classification
OMG	Ref
GMG	15.833 (3.945-63.540)	≤0.001	7.795 (1.629-37.296)	0.010
Thymoma
Without	Ref
With	5.000 (1.560-16.028)	0.007	1.268 (0.237-6.799)	0.782
AchR-Ab (nmol/L)	1.193 (1.052-1.353)	0.006	1.064 (0.920-1.230)	0.405
Treatment
Pyridostigmine	Ref
Glucocorticoid	3.667 (0.522-25.773)	0.192
Immunosuppressant	1.358 (0.454-4.059)	0.584

Abbreviations: OMG: ocular myasthenia gravis; GMG: generalized myasthenia gravis; MGFA: Myasthenia Gravis Foundation of America; AchR-Ab: acetylcholine receptor antibodies.